tradingkey.logo

Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia

ReutersApr 24, 2025 12:17 PM

- Coya Therapeutics Inc COYA.O:

  • COYA THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS OF AN INVESTIGATOR-INITIATED OPEN LABEL STUDY WITH LOW-DOSE IL-2 AND CTLA4-IG COMBINATION TREATMENT IN FIVE PATIENTS WITH MILD TO MODERATE FRONTOTEMPORAL DEMENTIA

  • COYA THERAPEUTICS INC - STUDY SHOWS SIGNIFICANT INCREASE IN TREG NUMBERS AND FUNCTION

  • COYA THERAPEUTICS INC - FTD PATIENTS SHOW MINIMAL TO NO COGNITIVE DECLINE IN STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI